PL2252317T3 - Leczenie zwyrodnienia plamki żółtej - Google Patents

Leczenie zwyrodnienia plamki żółtej

Info

Publication number
PL2252317T3
PL2252317T3 PL09709784T PL09709784T PL2252317T3 PL 2252317 T3 PL2252317 T3 PL 2252317T3 PL 09709784 T PL09709784 T PL 09709784T PL 09709784 T PL09709784 T PL 09709784T PL 2252317 T3 PL2252317 T3 PL 2252317T3
Authority
PL
Poland
Prior art keywords
treatment
macular degeneration
macular
degeneration
Prior art date
Application number
PL09709784T
Other languages
English (en)
Inventor
Rajendra Kumar-Singh
Siobhan M Cashman
Kasmir Ramo
Original Assignee
Univ Tufts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tufts filed Critical Univ Tufts
Publication of PL2252317T3 publication Critical patent/PL2252317T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/164Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09709784T 2008-02-15 2009-02-13 Leczenie zwyrodnienia plamki żółtej PL2252317T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6606208P 2008-02-15 2008-02-15
US6628808P 2008-02-19 2008-02-19
US7065008P 2008-03-25 2008-03-25
EP09709784.4A EP2252317B1 (en) 2008-02-15 2009-02-13 Treatment of macular degeneration
PCT/US2009/000947 WO2009102488A2 (en) 2008-02-15 2009-02-13 A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration

Publications (1)

Publication Number Publication Date
PL2252317T3 true PL2252317T3 (pl) 2014-09-30

Family

ID=40957438

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09709784T PL2252317T3 (pl) 2008-02-15 2009-02-13 Leczenie zwyrodnienia plamki żółtej

Country Status (9)

Country Link
US (1) US8324182B2 (pl)
EP (1) EP2252317B1 (pl)
JP (2) JP5697027B2 (pl)
AU (1) AU2009215118B2 (pl)
CA (1) CA2715373C (pl)
DK (1) DK2252317T3 (pl)
ES (1) ES2478820T3 (pl)
PL (1) PL2252317T3 (pl)
WO (1) WO2009102488A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
WO2012016162A2 (en) * 2010-07-29 2012-02-02 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
CN102844053B (zh) 2009-11-25 2015-08-05 洛马林达大学医学中心 基于壳聚糖的止血织物
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
AU2011336702B2 (en) * 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
US20150297674A1 (en) * 2012-03-12 2015-10-22 Loma Linda University Medical Center Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or disease
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
EP3892291A1 (en) * 2014-08-28 2021-10-13 Tufts University Compositions, methods and kits for treating complement related disorders
ES2992014T3 (es) * 2018-02-12 2024-12-05 Tufts College CD59 para inhibir la activación del inflamasoma
CN113748213A (zh) * 2019-03-29 2021-12-03 公立大学法人横滨市立大学 筛选方法及毒性评价方法
CN113041360A (zh) * 2021-04-01 2021-06-29 深圳廷美奥生物技术有限公司 一种用于治疗年龄相关性黄斑变性的药物
WO2023089564A1 (en) 2021-11-19 2023-05-25 Janssen Biotech, Inc. Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59
WO2025074268A1 (en) * 2023-10-02 2025-04-10 Janssen Biotech, Inc. Methods for treating macular degeneration

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
AU4404785A (en) 1984-05-25 1985-12-31 Dana-Farber Cancer Institute, Inc. Ltr vectors, methods of preparation and use
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
US5112767A (en) 1988-03-04 1992-05-12 University Of Southern California Vectors with enhancer domains
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
WO1990002797A1 (en) 1988-09-15 1990-03-22 North Carolina State University Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
WO1990013641A1 (en) 1989-05-10 1990-11-15 Sloan-Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
JP3249516B2 (ja) 1990-10-31 2002-01-21 ソマティクス セラピー コーポレイション 遺伝子治療のためのレトロウイルスのベクター
US5122767A (en) 1991-01-10 1992-06-16 Northern Telecom Limited Saw device tapped delay lines
DE69131908T3 (de) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU2001261103B2 (en) * 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030086940A1 (en) 2001-08-10 2003-05-08 Cristina Costa Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
EP2433642B1 (en) 2005-10-21 2016-12-07 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
CA2678774A1 (en) 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
US9617940B2 (en) 2014-08-14 2017-04-11 General Electric Company Engine diagnostic system and an associated method thereof

Also Published As

Publication number Publication date
WO2009102488A3 (en) 2009-10-08
EP2252317B1 (en) 2014-04-09
JP5697027B2 (ja) 2015-04-08
DK2252317T3 (da) 2014-07-14
EP2252317A2 (en) 2010-11-24
AU2009215118A1 (en) 2009-08-20
US20110015136A1 (en) 2011-01-20
US8324182B2 (en) 2012-12-04
JP2011514329A (ja) 2011-05-06
CA2715373C (en) 2019-11-05
AU2009215118B2 (en) 2015-01-22
WO2009102488A2 (en) 2009-08-20
EP2252317A4 (en) 2012-02-15
CA2715373A1 (en) 2009-08-20
JP2015063534A (ja) 2015-04-09
ES2478820T3 (es) 2014-07-23

Similar Documents

Publication Publication Date Title
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
IL208354A0 (en) Methods of treatment
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
PL2187880T3 (pl) Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej
NO2016023I1 (no) Glycerol fenylbutyrat
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
GB0915515D0 (en) Treatment of vasculoproliferative conditions
PT2435825E (pt) Métodos para o tratamento de doenças
ZA201008201B (en) Novel compositions and methods for treating hyperproliferative diseases
IL206491A0 (en) Treatment of produce
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
IL218282A0 (en) Treatment of macular degeneration
GB0900599D0 (en) Treatment
IL213198A (en) Preparation for the treatment of primary thrombocythemia
EP2164494A4 (en) Methods of Treatment
ZA201108151B (en) Method and composition for treating macular degeneration
IL213550A0 (en) Method for treating macular degeneration
GB0913968D0 (en) Treatment
GB0723100D0 (en) Treatment of HFnEF
GB0625844D0 (en) The treatment of macular degeneration
PL2263454T3 (pl) Kompozycja uzdatniająca
GB201001521D0 (en) Treatment
EP2485614A4 (en) MACHINING FOLDED ARTICLES
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
AU2009904097A0 (en) Treatment of Macular Degeneration